CCL5 and non-small cell lung carcinoma: PARP inhibitors generate cytoplasmic chromatin fragments with micronuclei characteristics which activate cGAS-STING, downstream type I interferon signalling and chemokine ligand 5 (CCL5) secretion in excision repair cross-complementation group 1 (ERCC1)-defective non-small cell lung cancer (NSCLC) cells (173).